Objectives: Immune checkpoint inhibitors (ICI) are associated with immune-related adverse events (irAE), including autoimmune rheumatologic
diseases. The Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO) undertook a survey to understand the needs of Canadian
rheumatologists.
Methods: A 25-item survey was developed. It was distributed via electronic mail to 574 members of the Canadian Rheumatology Association (CRA).
Results were summarized using descriptive statistics.
Results: Over 25% of the respondents were not familiar with irAE. 48.7% reported being ‘slightly or not confident’ in providing advice regarding
irAE.
Conclusion: The survey highlighted the strong rationale to develop clinical practice guidelines for managing irAE.